SMT201600156B - Trattamento dell’osteoartrite - Google Patents

Trattamento dell’osteoartrite

Info

Publication number
SMT201600156B
SMT201600156B SM201600156T SM201600156T SMT201600156B SM T201600156 B SMT201600156 B SM T201600156B SM 201600156 T SM201600156 T SM 201600156T SM 201600156 T SM201600156 T SM 201600156T SM T201600156 B SMT201600156 B SM T201600156B
Authority
SM
San Marino
Prior art keywords
osteoartritis
treatment
Prior art date
Application number
SM201600156T
Other languages
English (en)
Inventor
John Allan Hamilton
Andrew David Cook
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600156(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of SMT201600156B publication Critical patent/SMT201600156B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SM201600156T 2008-12-22 2016-06-01 Trattamento dell’osteoartrite SMT201600156B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (1)

Publication Number Publication Date
SMT201600156B true SMT201600156B (it) 2016-08-31

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600156T SMT201600156B (it) 2008-12-22 2016-06-01 Trattamento dell’osteoartrite

Country Status (19)

Country Link
US (4) US9243061B2 (it)
EP (2) EP2376121B2 (it)
JP (3) JP5727379B2 (it)
KR (2) KR101898982B1 (it)
CN (2) CN102271705A (it)
AU (1) AU2009329814B2 (it)
BR (1) BRPI0918356B1 (it)
CA (1) CA2746827C (it)
CY (1) CY1117698T1 (it)
DK (1) DK2376121T4 (it)
ES (2) ES2572368T5 (it)
HK (1) HK1226938A1 (it)
HR (1) HRP20160577T4 (it)
HU (1) HUE028615T2 (it)
PL (1) PL2376121T5 (it)
RU (2) RU2011127334A (it)
SI (2) SI2376121T2 (it)
SM (1) SMT201600156B (it)
WO (1) WO2010071924A1 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
EP3916013A1 (en) 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
WO2019034985A1 (en) * 2017-08-14 2019-02-21 Zynerba Pharmaceuticals, Inc. METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA2062975A1 (en) 1989-07-14 1991-01-15 Gail F. Seelig Antagonists of gm-csf derived from the carboxyl terminus
WO1991002063A1 (en) 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
EP0673389A1 (en) 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
WO2003035048A2 (en) * 2001-10-26 2003-05-01 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
DE602005020743D1 (de) † 2004-02-11 2010-06-02 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
WO2005094889A1 (ja) * 2004-03-31 2005-10-13 Chugai Seiyaku Kabushiki Kaisha 関節炎症治療剤又は予防剤
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
CA2575439A1 (en) * 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
ME02191B (me) 2005-04-18 2016-02-20 Amgen Res Munich Gmbh Protutijela koja neutraliziraju ljudski čimbenik stimuliranja kolonija makrofaga
NZ564027A (en) 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR20080077237A (ko) * 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷
RS55526B1 (sr) * 2006-02-08 2017-05-31 Morphotek Inc Antigenski gm-csf peptidi i antitela gm-csf
ES2395839T3 (es) 2006-03-27 2013-02-15 Medimmune Limited Miembro de unión para el receptor GM-CSF
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
US7879856B2 (en) * 2006-12-22 2011-02-01 Rigel Pharmaceuticals, Inc. Diaminothiazoles useful as Axl inhibitors
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
US20100297135A1 (en) 2007-11-12 2010-11-25 Crc For Asthma And Airways Ltd. Epitope for neutralizing antibodies
MX2010005291A (es) * 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
MX2010010503A (es) † 2008-03-24 2010-11-09 Abbott Biotech Ltd Metodos y composiciones para tratar perdida osea.
CN102037016B (zh) 2008-04-28 2015-06-03 卡罗拜奥斯制药公司 针对粒细胞巨噬细胞集落刺激因子的抗体
ES2978209T3 (es) † 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
ES2886063T3 (es) 2021-12-16
CA2746827A1 (en) 2010-07-01
HUE028615T2 (en) 2016-12-28
HRP20160577T1 (hr) 2016-07-29
EP2376121B2 (en) 2021-06-09
DK2376121T4 (da) 2021-08-16
US20160185868A1 (en) 2016-06-30
KR101898982B1 (ko) 2018-09-14
US20200247895A1 (en) 2020-08-06
US20180066062A1 (en) 2018-03-08
KR20170128630A (ko) 2017-11-22
RU2016102339A (ru) 2018-11-21
EP2376121A4 (en) 2013-04-03
RU2016102339A3 (it) 2019-07-29
HK1226938A1 (en) 2017-10-13
EP2376121A1 (en) 2011-10-19
BRPI0918356B1 (pt) 2022-03-08
PL2376121T5 (pl) 2021-09-27
US9243061B2 (en) 2016-01-26
JP6458086B2 (ja) 2019-01-23
KR20110128273A (ko) 2011-11-29
RU2712273C2 (ru) 2020-01-28
AU2009329814B2 (en) 2015-06-18
JP2015143233A (ja) 2015-08-06
KR101799264B1 (ko) 2017-11-20
RU2011127334A (ru) 2013-01-27
PL2376121T3 (pl) 2016-12-30
BRPI0918356A2 (pt) 2020-10-06
HRP20160577T4 (hr) 2021-08-20
AU2009329814A1 (en) 2010-07-01
ES2572368T5 (es) 2021-12-16
EP2376121B1 (en) 2016-03-09
CN106397591A (zh) 2017-02-15
CY1117698T1 (el) 2017-05-17
EP3056217B1 (en) 2021-06-30
JP5727379B2 (ja) 2015-06-03
US20120003234A1 (en) 2012-01-05
CN102271705A (zh) 2011-12-07
ES2572368T3 (es) 2016-05-31
EP3056217A1 (en) 2016-08-17
SI2376121T1 (sl) 2016-07-29
JP2012512815A (ja) 2012-06-07
SI2376121T2 (sl) 2021-11-30
CA2746827C (en) 2018-01-23
JP2017200933A (ja) 2017-11-09
DK2376121T3 (en) 2016-05-30
WO2010071924A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
PL2621523T3 (pl) Sposoby leczenia choroby autoimmunologicznej z zastosowaniem biokompatybilnych bioabsorbowalnych nanosfer
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0916931A2 (pt) agentes terapêuticos
DK2222272T3 (da) Behandling af luftvejssygdom
PT2448582T (pt) Compostos e composições terapêuticas
PL2506850T3 (pl) Sposoby podawania terapii pirfenidonem
BRPI0910854A2 (pt) métodos de tratamento
DK2330887T3 (da) Behandlingsindretning
PL2435825T3 (pl) Sposoby leczenia chorób
GB0818074D0 (en) Treatment of biofilms
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
SMT201600332B (it) Composizioni e metodi per l’aumento dell’attivitàtelomerasica
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
DK2252317T3 (da) Behandling af makuladegeneration
EP2367606A4 (en) BONDING BEHAVIOR SHOWING TOY
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
EP3381471C0 (en) PAIN TREATMENT
DK2501381T3 (da) Behandling af atrieflimmer
HRP20160577T1 (hr) Liječenje osteoartritisa
CU23884B1 (es) Derivados de dibenzotiazepina
BRPI0915761A2 (pt) composto de heterociclila para tratamento de doença cardiovascular
DK2173197T3 (da) Fremgangsmåde